Insmed Announces Proposed $650 Million Public Offering of Common Stock

Core Viewpoint - Insmed Incorporated plans to offer and sell $650 million of its common stock in an underwritten public offering, with an additional option for underwriters to purchase up to $97.5 million more [1] Group 1: Offering Details - The public offering is subject to market conditions and there is no assurance regarding the completion or terms of the offering [1] - Goldman Sachs & Co. LLC and Leerink Partners are acting as joint book-running managers for the offering [2] - The offering is made pursuant to Insmed's shelf registration statement on Form S-3, which became effective on May 19, 2023 [3] Group 2: Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for serious diseases [5] - The company has a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [5] - Insmed's advanced programs include a therapy approved in the U.S., Europe, and Japan for a chronic lung disease [5] - The company is headquartered in Bridgewater, New Jersey, with offices and research locations in the U.S., Europe, and Japan [6]